Abramson Cancer Center News


FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania

The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene.

Read More

Recent News

Share This Page: